Member Info for LovableLumax

So we get the ASCO text after close this evening and presumably an RNS on Friday at 7am. No standard of care for SGC with a very low bar in PFS so if we are to double this or even better it’s a shoe-in for an accelerated pathway. We won’t have OS completed but to have an accelerated route it’s not needed if PFS is significantly improved upon. The question is will this be announced imminently which will surely accelerate talks or will they wait, not sure why they’d wait or delay?

Either way with the lifetime dose being lifted due to impeccable safety (targeting) and signs of efficacy in a very hard to treat cancer with much improved PFS an accelerated path is en route. Interested to see how they have planned the announcement.

We only raised £10m and my guess is that's the minimum the auditor demanded for sign off so there's a plan or they would have taken more which they could have done. We will surely know in the coming weeks and the BoD won’t let it get to Q4 before cash arrives. We’ll surely know early Q3.

On here with the sole surprise of spreading FUD. Some have reinvented themselves (again) and although have moved on from an imaginary half-life issue their agenda the same.

Nothing has changed from

Science day, cash to (early) Q1, we will not deal on 6103 this early so waiting for data end of the year. SGC 6000 PFS data was superb in P1, P1a continued the trend and we will see impressive data before the month's end. Given CC said watch this space re accelerated pathway I'm hopeful it'll be announced soon as even if PFS still ongoing if it's 3 times the benchmark we can still be granted it which will accelerate discussions.

We only raised £10m and my guess is that's the minimum the auditor demanded for sign off so there's a plan or they would have taken more.

Heights want to make money so they're not going to convert both and trash the share price. They'll be following news and sentiment closely. The science is amazing and come year end little Avacta could be on the verge of transforming tumour treatment. In the meantime (coming weeks) show why lifetime dox limit unbelievably taken away after c40 years, show say 3 times PFS in SGC, accelerated pathway and then TNBC/STS data end of June and we roll on and strengthen balance sheet.

In that time thorn and others will still obsess with Avacta and try and sew doubt and the while patients in both 6000 and 6103 are getting kinder treatments stopping tumours that were progressing.

Oh and I suspect news on 6207 won't be long behind 6000 data. Onwards and upwards.

I strongly believe if they didn’t have a plan they were sure of executing they’d have taken more than £10m in the recent placing. It looks like they took the minimum the auditor would allow for audit sign off.

I agree if a deal doesn’t land before Sept they’ll be huge pressure on share price but I can’t see that being the case. Just a view.

I like the honesty. We are discussing lots but want to retain 6103 until initial data end of the year. We won't take 6000 into P2/3 and we will need updated PFS with an accelerated pathway which I hope will be in the coming weeks and months. Remember PFS for SGC was less than 4 months so we will hopefully be 3 times better than that which will feed into OS. FDA will surely be happy to give an accelerated pathway with 3 fold PFS and then a partner follows with 7 years exclusivity if approved.

CC sounds like a straight shooter unlike many AIM CEOs so I take what she says as given. She doesn't seem to over egg or duck questions.

What a stupid question for the moderator to ask when CC had just answered one on accelerated pathway.

And I bet you don’t submit a question in the correct forum but will continue to ask them on here!!

Wyn the most prolific poster and eggy with the highest number of profiles. Great work.

If Avacta doesn't announce a partner to take 6000 into a registrational P2 by August it'll be a failure. My bet is once will be announced June at ASCO or soon after in July.

Https://x.com/rah00084/status/2056639110832337166?s=46

“Agreement on dose selection for subsequent trials” suggests #AVCT has agreed the Phase 2 AVA6000 trial design with the FDA. I.e. Project Optimus.

We have been told the 6000 will not extend beyond Phase 1b without a partner.

But have we been told they have confirmed AVA6000 trial design with FDA before today? If so, that passed me by

Https://x.com/bigbitenow/status/2056622406035230982?s=46

The #AVCT interims read very well.

Some of my favourite parts as we move into late H1 2026.

"The first patients have been treated in Phase 1a of the program with the FOCUS-01 trial initiating in Q1 2026 as planned."

"We believe that AVA6103 will enable patients to obtain the therapeutic benefit associated with delivering exatecan directly to tumors in a sustained release mechanism, while limiting systemic exposure that was associated with poor tolerability in the original development of conventional exatecan."

We all know what assuming can lead to, but they surely have seen evidence in these "first patients" that allows them to "believe" in AVA6103 so much.

"We expect multiple data updates in the AVA6000 program in all groups from the Phase 1b expansion cohorts, in H1 2026."

"Our team continues to explore multiple commercial opportunities with potential strategic partners.  Our new data in both clinical programs are anticipated to be significant advances in moving these ongoing conversations forward."

Give me the data, and I'll give you a deal.

That is more than enough for me.

They have cash until early 2027 and surely will get a SGC deal in the coming weeks. They usually burn £1.5m a month but that has increased with R&D costs and setting up new sites so will come back down. They could've taken more than £10m but wanted to limit dilution ahead of 6000 data.

Nothing new. The exciting but surely comes in the next couple of months re an accelerated route for SGC and a partner to take it forward. I’d sell all rights and forget royalties to get as much cash as pos for 6103. An exciting few months and beyond.

If 6103 does what it did preclinically it will be amazing for solid tumour treatment (given don’t need high FAP) and if it improves like 6000 did as humans have less FAP in circulation it could be one of the most important therapies developed. I suspect the latter as humans won’t suddenly develop more circulating FAP.

Been forward sold surely hence a few chunky sells over last couple of days.

Https://x.com/rah00084/status/2054242133607866785?s=46

It took enhertu 3 escalations to get to optimum dose so in theory we could get there in June. Remember we are delivering more payload directly into TME and the volume (if following mice models) will likely be even more impressive. In addition the payload is 10 to 20 times more potent so we could see some impressive results and I’d wager after the initial low dose as with BOIN we can accelerate. A huge few months loaded and of course in the meantime 6000 data due.

I reckon gemstar sold as thought we'd drift south. Posts before science day and soon after suggest so. From bullish to -

I assume from the SP reaction that the conference once again has still not cleared up the half life issue

I share your sentiment for definite. Was lamely trying to appeal to the traders to hold on for 100p+! I'm a LTH and not a trader (would have more cash or shares had I followed Viking) and am relaxed if we fall before I believe a head north as the chemistry/IP is seemingly working as designed. Onwards and upwards indeed.

Most of us ridicule especially on AiM but when heavily retail and traded as Avacta is charts so count albeit news trumps it. Weekly charts always seem better plays in my very limited experience and this guy has called Avacta very well for many years. Mostly to the annoyance of holders as was more often predicted to fall. This was back end of Feb -

https://x.com/borg74/status/2027275002467537244?s=46

Https://x.com/blueberrymgmnt/status/1555630060786384897?s=46

To be fair although most of us thought 6000 sexy enough many large pharma didn’t agree due to ADCs but with 6103 that’s changed IMO and these data with biomarker (FAP) proven the interest in the platform should only increase.